(ADVB) Advanced Biomed Inc. Business Model Canvas Research

Research institutions and universities help Advanced Biomed Inc. turn microfluidics and oncology biomarker ideas into validated products. They support nanoliter-scale method work, peer-reviewed publications, and tech proof points for A+LCGuard, which lifts scientific credibility and speeds adoption.

• Validate assays and biomarker data
• Co-develop publication-ready methods
• Strengthen A+LCGuard credibility

Advanced Biomed Inc. depends on specialized suppliers for biochip components, reagents, and device parts, plus manufacturing partners that can scale chips, kits, and devices without losing quality. These links protect consistency, support supply continuity, and reduce the risk of production delays.

• Secure critical biochip inputs
• Scale production at commercial volume
• Keep quality and supply stable

Clinical validation is core for Advanced Biomed Inc. because cancer tests must prove they work in real hospital and lab workflows. In 2022, cancer caused about 20.0 million new cases and 9.7 million deaths worldwide, so even small gains in accuracy matter; the NLST showed low-dose CT cut lung-cancer mortality by 20%.

• Proves detection and diagnosis performance
• Builds trust with hospitals and labs
• Supports early lung-cancer screening claims

Advanced Biomed Inc. uses its medical clinics in the PRC to deliver care directly, test products in real settings, and turn R and D into paid clinical use. This clinic layer supports commercialization by linking treatment demand, physician feedback, and revenue capture in one operating channel.

• Direct clinic-based service delivery
• Real-world product deployment
• Faster R and D-to-revenue conversion

Advanced Biomed Inc. depends on a small but highly specialized scientific and engineering team in microfluidics, oncology, diagnostics, and device design to build systems, validate assays, and lift performance. This human capital drives innovation speed, and the company has not publicly disclosed a 2026 headcount, so team depth is a key execution risk.

• Microfluidics expertise shapes system design
• Oncology and diagnostics skills validate assays
• Device engineers improve reliability and speed

Advanced Biomed Inc.'s New York headquarters, paired with operations in Taiwan and the PRC, supports cross-border oversight of R and D, commercialization, and clinical use. Its clinic footprint gives direct access to patients and care delivery, so product testing and market rollout stay tied to real-world use.

• New York: global coordination hub
• Taiwan and PRC: operating and clinical reach

A+CellScan and its chips and kits link capture, staining, and analysis in one system, so labs can move from sample prep to immunostaining and interpretation without switching tools. That cuts workflow steps, lowers handling errors, and makes daily use simpler for research and clinical teams.

• One ecosystem for capture, staining, analysis
• Fewer handoffs, less workflow complexity
• Faster path from sample to result

A+LCGuard targets early lung cancer screening, a high-value area where low-dose CT has cut lung-cancer mortality by about 20% in high-risk groups. That widens Advanced Biomed Inc.'s platform from detection to earlier intervention, where earlier stage finds can drive better clinical and commercial value.

• Early screening use case
• Higher-value detection segment
• Broader platform reach

Advanced Biomed Inc.’s PRC clinic ops create direct, consumer-facing ties with patients through screening, testing, and follow-up. That service layer turns the business from a pure provider into an ongoing patient relationship model, with care touchpoints that can drive repeat visits and trust.

• Direct patient contact in PRC clinics
• Screening, testing, and follow-up

Scientific communication is a core customer relationship for Advanced Biomed Inc., especially in oncology diagnostics, where peer-reviewed publications, data sharing, and conference talks shape trust. In a market where buyers need clear proof of performance and use cases, strong scientific credibility helps customers judge fit before adoption.

• Build trust with peer-reviewed evidence.
• Share data on performance and use.
• Use conferences to reach clinicians.
• Scientific credibility matters most in oncology.

Scientific conferences and peer-reviewed publications are core channels for Advanced Biomed Inc. to prove oncology performance, with major medical meetings drawing tens of thousands of clinicians and researchers each year. For novel microfluidic platforms, published data matters most because it drives trust, market education, and later-stage adoption.

• Build credibility with peer review
• Showcase oncology use cases fast
• Best for novel microfluidic tools

Advanced Biomed Inc. uses corporate and investor communications to explain product updates, development milestones, and its path to commercialization. Because Advanced Biomed Inc. is an investment holding company, investor relations also help track capital use, portfolio direction, and funding needs, while digital channels widen partner outreach.

• Explains products and progress
• Supports investor relations
• Reaches partners online

Research institutions and Advanced Biomed Inc. use this segment to study circulating tumor cells and linked biomarkers for cancer biology, while biotech firms can apply the platform to assay development and translational research. These buyers care most about flexible workflows and high data quality, because that supports reproducible results and faster moves from lab testing to clinical use.

• Research use: CTC and biomarker studies
• Biotech use: assay development, translational work
• Key need: flexibility plus data quality

Advanced Biomed Inc. clinics serve patients in mainland China, a market of about 1.4 billion people. These customers may seek screening, testing, and follow-up care, so the segment supports consumer-facing diagnostics and recurring care visits.

• Direct PRC patient access for screening and testing
• Follow-up visits can lift repeat use
• Large mainland market supports local demand

Advanced Biomed Inc. must fund testing, approvals, documentation, audits, and ongoing oversight to meet medical device and clinic rules. For products sold in the U.S., FDA 510(k) clearance can take months and user fees plus quality-system work often push compliance into a major fixed cost, but it is what keeps market access open and patients safe.

Compliance spend is not optional; it protects revenue, reduces recall risk, and supports clinic licensure. In 2025-2026, firms are still facing tighter quality and reporting demands, so every control step adds cost but also lowers the chance of shutdowns, penalties, and failed approvals.

• Testing and validation costs
• FDA and clinic approvals
• Quality system audits
• Documentation and traceability
• Patient safety and market access

Selling, general, and administrative costs fund commercialization, covering sales, marketing, finance, and corporate admin. For Advanced Biomed Inc., the New York headquarters also adds overhead for management and investor relations, so these costs support both operating and holding company roles.

• Sales and marketing drive launch
• Finance and admin keep control
• NY HQ lifts overhead
• Investor relations support capital access

Hospitals, labs, and research clients can pay Advanced Biomed Inc. for assay execution and analysis, turning testing into a recurring institutional revenue stream. Contract packages can bundle devices, kits, and technical support, which lifts order value and makes revenue less tied to one-off product sales.

• Recurring contract-based testing

• Bundles devices, kits, and expertise

• Targets hospitals, labs, researchers

Advanced Biomed can earn non-product income from licensing its microfluidic and assay IP, plus returns on equity or strategic investments. In its latest verified 2025 filings, this stream was not broken out as a separate line item, so it should be treated as supplemental to core product and service sales.

• Monetizes proprietary IP.
• Can add non-dilutive cash.
• Complements product revenue.